Related references
Note: Only part of the references are listed.Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Paul Guedeney et al.
EUROPEAN HEART JOURNAL (2022)
Satin therapy increases lipoprotein(a) levels
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease
Jonathan Golledge et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
Maria Francesca Greco et al.
JOURNAL OF CLINICAL MEDICINE (2020)
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein (a) particles in statin-treated patients with elevated lipoprotein(a)
Gerald F. Watts et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek et al.
EUROPEAN HEART JOURNAL (2020)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek et al.
EUROPEAN HEART JOURNAL (2020)
Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience
Muhammed T. Gurgoze et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P. Wilson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
Application of PCSK9 Inhibitors in Practice Part 2: The Patient Experience
Tina M. Kaufman et al.
CIRCULATION RESEARCH (2019)
Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention
Christian M. Madsen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
HEART UK consensus statement on Lipoprotein(a): A call to action
Jaimini Cegla et al.
ATHEROSCLEROSIS (2019)
Lipoprotein(a) catabolism: a case of multiple receptors
Sally P. A. McCormick et al.
PATHOLOGY (2019)
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
Gerald F. Watts et al.
EUROPEAN HEART JOURNAL (2018)
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies A Mendelian Randomization Analysis
Stephen Burgess et al.
JAMA CARDIOLOGY (2018)
From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients
Maria G. Zenti et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Gerald F. Watts et al.
CIRCULATION (2017)
Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres
Monika Kohli et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2017)
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9
Jonathan B. Edmiston et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Cognitive Function in a Randomized Trial of Evolocumab
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis
Danish Saleheen et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©
Terry A. Jacobson et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2017)
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Current therapies for lowering lipoprotein (a)
Julian C. van Capelleveen et al.
JOURNAL OF LIPID RESEARCH (2016)
PCSK9 Association With Lipoprotein(a)
Hagai Tavori et al.
CIRCULATION RESEARCH (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Structure, function, and genetics of lipoprotein (a)
Konrad Schmidt et al.
JOURNAL OF LIPID RESEARCH (2016)
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
Frederick J. Raal et al.
JOURNAL OF LIPID RESEARCH (2016)
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
Borge G. Nordestgaard et al.
JOURNAL OF LIPID RESEARCH (2016)
High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study
Anne Langsted et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia
Dick C. Chan et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
An assessment by the Statin Muscle Safety Task Force: 2014 update
Robert S. Rosenson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Lipoprotein(a) Levels in Familial Hypercholesterolemia An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation
Rodrigo Alonso
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
Nihar R. Desai et al.
CIRCULATION (2013)
Lipoprotein(a)-cholesterol: A significant component of serum cholesterol
Kiyoko Kinpara et al.
CLINICA CHIMICA ACTA (2011)
PCSK9: a convertase that coordinates LDL catabolism
Jay D. Horton et al.
JOURNAL OF LIPID RESEARCH (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Share Paper
